title: Dextromethorphan: a case study on addressing abuse of a safe and effective drug.
abstract: Dextromethorphan is a safe, effective cough suppressant, available without a prescription in the United States since 1958. Due to a perceived prevalence of abuse of dextromethorphan by teens, in 2007 the Drug Enforcement Administration requested the Food and Drug Administration evaluate whether dextromethorphan should be recommended for scheduling under the Controlled Substances Act. The Food and Drug Administration held an Advisory Committee meeting in 2010 to provide a scientific and medical evaluation of dextromethorphan and its abuse potential.
  
  
  
  To address reports of abuse, particularly by teens in the United States, the Consumer Healthcare Products Association initiated an abuse mitigation plan in 2010 with specific goals related to awareness of the behavior, perception of risk, social disapproval, and access to the products. In identifying abuse interventions, experts acknowledge that substance abuse among teens is a highly complex behavior and indicate that the best course of action is to address prevention by focusing on the factors that impact teen behavior.
  
  
  
  It is noteworthy that the annual prevalence of over-the-counter cough medicine abuse has sharply decreased since 2010. While a true cause-and-effect relationship cannot be assured, the Consumer Healthcare Products Association and its member companies believe that the increased awareness of the issue since the 2010 Food and Drug Administration Advisory Committee meeting, and the subsequent implementation of a well-delivered and targeted abuse mitigation plan that addressed the levers influencing teen decisions is contributing to the observed reduction in abuse. During the period of 2010-2015, reported abuse of dextromethorphan by 8(th), 10(th), and 12(th) graders decreased 35 %. The authors believe this reduction supports the view of the Consumer Healthcare Products Association at the outset of the abuse mitigation plan effort and today: Controlled substance scheduling or prescription requirements would result in a reduction in the legitimate use of this medicine that has benefits that far outweigh its risks. Instead, there are more targeted, more effective, and less disruptive interventions to address dextromethorphan abuse.
authors.affiliation: Consumer Healthcare Products Association, Washington, DC, USA.
authors.forename: David C
authors.initials: DC
authors.lastname: Spangler
authors.affiliation: Consumer Healthcare Products Association, Washington, DC, USA. kloyd@chpa.org.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Loyd
authors.affiliation: Consumer Healthcare Products Association, Washington, DC, USA.|Growth Energy, Washington, DC, USA.
authors.forename: Emily E
authors.initials: EE
authors.lastname: Skor
mesh_terms: D000293:Adolescent; D000996:Antitussive Agents / Q000009:adverse effects; D003915:Dextromethorphan / Q000009:adverse effects*; D005260:Female; D006266:Health Education / Q000379:methods*; D006801:Humans; D008297:Male; D016730:Program Development; D019966:Substance-Related Disorders / Q000453:epidemiology / Q000517:prevention & control*; D014481:United States / Q000453:epidemiology
chemical_list: D000996:Antitussive Agents; D003915:Dextromethorphan
keywords: At-risk youth; Dextromethorphan; Drug abuse; Prevention; Substance abuse